Letrozole
Established medicineAlso known as Femara, Letrozol.
Recent clinical, regulatory, research and industry developments relating to this drug.
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse
Label change: LETROZOLE (ANDA090292)
Generic approval: LETROZOLE (ANDA220438)
Chronic Aromatase Inhibition Attenuates Synaptic Plasticity in Ovariectomized Mice.
Generic approval: LETROZOLE (ANDA090292)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- The New England journal of medicine4
- Annals of oncology : official journal of the European Society for Medical Oncology2
- Annals of the American Thoracic Society1
- Breast cancer research and treatment1
- eNeuro1
- Journal for immunotherapy of cancer1
- Campone M2
- Diéras V2
- Finn RS2
- Gelmon K2
- Im SA2
- Iwata H2
- Lu DR2
- Martin M2
- Mayo Clinic2
- 3 Swedish Medical Center1
- 9 Stanford University1
- Abramson Cancer Center1
- Advanced Cancer Translational Research Institute1
- Aichi Cancer Center1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Letrozole, with an overlapping disease area.
Studied across 2 of the same disease areas as Letrozole in the shared literature.
Studied across the same disease area as Letrozole in the shared literature.
Studied across the same disease area as Letrozole in the shared literature.
Studied across the same disease area as Letrozole in the shared literature.
Studied across the same disease area as Letrozole in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.